University Health Network

Running trials

• Not yet recruiting

  Functional Electrical Stimulation Plus High Intensity Interval Training at Home

  NCT07773974· University Health Network, Toronto· Source

• Not yet recruiting

  Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial

  NCT07820033· Phase 2· University Health Network, Toronto· Source

• Recruiting

  GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

  NCT07297667· Phase 1· Canadian Cancer Trials Group· Source

• Recruiting

  Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

  NCT07341191· Phase 2· Canadian Cancer Trials Group· Source

• Enrolling by invitation

  Implementation of Acute Heart Failure Checklist

  NCT07727304· Ottawa Hospital Research Institute· Source

• Recruiting

  Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

  NCT06943573· Phase 2· Lakshmi N Yatham· Source

• Recruiting

  SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

  NCT06955260· Phase 3· Subodh Verma· Source

• Recruiting

  Cannabinoids for Osteoarthritis Pain Effectiveness Trial

  NCT06878417· University Health Network, Toronto· Source

• Recruiting

  Feasibility and Safety of a Combined Augmented Reality and Functional Electrical Stimulation System

  NCT07299734· Early phase 1· University Health Network, Toronto· Source

• Recruiting

  Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition

  NCT06452095· University Health Network, Toronto· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Taurine Supplementation in Long COVID

  NCT06721949· Phase 2/3· University of Alberta· Source

• Recruiting

  STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

  NCT06880523· Phase 2· Canadian Cancer Trials Group· Source

• Recruiting

  Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis

  NCT07298265· Charite University, Berlin, Germany· Source

• Not yet recruiting

  Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study

  NCT06887270· University Health Network, Toronto· Source

• Recruiting

  Effect of Hi-OxSR for the Treatment of Post COVID Condition

  NCT06928506· University Health Network, Toronto· Source

• Recruiting

  Using Cannabis to Treat Restless Legs Syndrome

  NCT06863740· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

  NCT07112170· University Health Network, Toronto· Source

• Recruiting

  Optimizing Recruitment to Drive Equitable Research Opportunity in Stroke Rehabilitation Trials in Canada

  NCT06576089· McMaster University· Source

• Recruiting

  Shorter and Safer Treatment Regimens for Latent TB

  NCT06498414· Phase 2/3· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners

  NCT06877598· University Health Network, Toronto· Source

• Recruiting

  Stimulating Postural Control to Augment Rehabilitation After Cerebral Stroke (SPARC): a Pilot Trial

  NCT06987682· University Health Network, Toronto· Source

• Recruiting

  A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  NCT06798012· Phase 2· Takeda· Source

• Recruiting

  PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

  NCT06871176· University Health Network, Toronto· Source

• Recruiting

  LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

  NCT06623461· Phase 2· Canadian Cancer Trials Group· Source

• Recruiting

  Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

  NCT06641791· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Recruiting

  Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

  NCT06780917· Centre for Addiction and Mental Health· Source

• Recruiting

  Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

  NCT06439225· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Predictors of Relapse in Major Depressive Disorder (PERFORM-D)

  NCT06746155· Abraham Nunes· Source

• Recruiting

  Radialis PET Imager for the Assessment of Neuritic Amyloid Plaque Burden

  NCT06757569· University Health Network, Toronto· Source

• Recruiting

  CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

  NCT06700304· Neuralink Corp· Source

• Recruiting

  Routine vs On-demand ECMO for Lung Transplantation

  NCT06615492· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Recruiting

  Digital Peer Navigation for Adolescents and Young Adults With Cancer

  NCT06193369· University Health Network, Toronto· Source

• Recruiting

  Inspiratory Muscle Training in Lung Transplant Candidates

  NCT06370832· University Health Network, Toronto· Source

• Recruiting

  Theta-Burst Stimulation for Bipolar Depression

  NCT06370988· Centre for Addiction and Mental Health· Source

• Recruiting

  A Registry for People With Lung Cancer

  NCT06424327· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  CfDNA in Hereditary And High-risk Malignancies 2

  NCT06726642· University Health Network, Toronto· Source

• Recruiting

  Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]

  NCT06216470· Phase 2· University Health Network, Toronto· Source

• Recruiting

  IVIM & OLINK in Sarcoma

  NCT05950594· Phase 2· University Health Network, Toronto· Source

• Recruiting

  The STOP-MED CTRCD Trial

  NCT06183437· Phase 4· Dinesh Thavendiranathan· Source

• Recruiting

  The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled Trial

  NCT05023785· University Health Network, Toronto· Source

• Recruiting

  ODYSSEE Kidney Health Trial

  NCT06274710· University Health Network, Toronto· Source

• Recruiting

  Feasibility of Early Swallowing and Speech Intervention for Head and Neck Cancer Patients Treated SURGically

  NCT06192771· University Health Network, Toronto· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

• Recruiting

  A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  NCT06131840· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

  NCT05904028· Phase 3· Jaeb Center for Health Research· Source

• Recruiting

  Durvalumab and Tremelimumab in Resectable HCC

  NCT05440864· Phase 2· University Health Network, Toronto· Source

• Recruiting

  An Innovative Master Platform for Clinical Trials in Mood Disorders

  NCT06408012· St. Joseph's Healthcare Hamilton· Source

• Active, not recruiting

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

Showing 50 of 120.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers5 recruiting
• Liver and biliary tract cancer5 recruiting
• Lung cancer5 recruiting
• Depression4 recruiting
• Heart failure4 recruiting
• Melanoma4 recruiting
• Sarcoma4 recruiting
• Bipolar disorder3 recruiting
• COPD3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Head and neck cancer3 recruiting
• Long COVID and ME/CFS3 recruiting
• Pancreatic cancer3 recruiting
• Prostate cancer3 recruiting
• Spinal cord injury3 recruiting
• Stroke3 recruiting
• Atrial fibrillation2 recruiting
• Chronic kidney disease2 recruiting
• Endometrial cancer2 recruiting
• Epilepsy2 recruiting
• Multiple myeloma2 recruiting
• Ovarian cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Colorectal cancer1 recruiting
• Congenital heart disease1 recruiting
• Diabetic eye disease1 recruiting
• Hepatitis B1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Kidney cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Osteoarthritis1 recruiting
• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Restless legs syndrome1 recruiting
• Retinitis pigmentosa1 recruiting
• Sickle cell disease1 recruiting
• Thalassaemia1 recruiting
• Thyroid cancer1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Terminated

  --SuPERIOR Trial--

  NCT06191250· Phase 2· University Health Network, Toronto· Source

• Terminated

  A Study of SGN-MesoC2 in Advanced Solid Tumors

  NCT06466187· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

  NCT06064929· Phase 1· HI-Bio, A Biogen Company· Source

• Completed

  RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

  NCT05513560· Phase 2/3· University Health Network, Toronto· Source

• Completed

  Descriptive Analysis of Real-world Data Collected with ME&MGopen

  NCT05566964· Ad scientiam· Source

• Completed

  Multifaceted Intervention Using Telehealth to Reduce the Risk of Falls and Fractures in Older Men

  NCT05927623· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Completed

  Pilot Open Label Use of the Hi-OXSR for the Treatment of Post COVID-19 Cognitive Dysfunction

  NCT06379620· Phase 1· University Health Network, Toronto· Source

• Completed

  Prediction of Muscle Responsiveness to FES Therapy

  NCT05462925· University Health Network, Toronto· Source

• Completed

  Time Restricted Eating and Cardiac Rehabilitation

  NCT05075317· University of Toronto· Source

• Completed

  Cognitive and Physical Training in Patients With Chronic Obstructive Pulmonary Disease Patients

  NCT05140226· University Health Network, Toronto· Source

• Completed

  Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

  NCT05227144· Phase 1· ORIC Pharmaceuticals· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

  NCT04968548· Nucleix Ltd.· Source

• Completed

  Rapid HCV Treatment Access for Persons Who Use Drugs

  NCT04677153· Johns Hopkins University· Source

• Completed

  MINDS Imaging Ancillary Study

  NCT05270356· University of Pittsburgh· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Terminated

  Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

  NCT04665375· Phase 4· University Health Network, Toronto· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT04644237· Phase 2· Daiichi Sankyo· Source

• Completed

  Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

  NCT04442048· Phase 3· Canadian Cancer Trials Group· Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Phase 1· Pfizer· Source

• Completed

  Subcutaneous Immunoglobulin for Myasthenia Gravis

  NCT04728425· Phase 2· University Health Network, Toronto· Source

• Completed

  Interactive Online Informational and Peer Support App for Patients with Low Anterior Resection Syndrome

  NCT04469426· Jewish General Hospital· Source

• Completed

  Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung

  NCT04182815· Auris Health, Inc.· Source

• Completed

  A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

  NCT03596866· Phase 3· Takeda· Source

• Completed

  A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  NCT03535740· Phase 2· Ariad Pharmaceuticals· Source

• Completed

  PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer

  NCT03455608· University Health Network, Toronto· Source

• Terminated

  Liver Transplantation for Early Intrahepatic Cholangiocarcinoma

  NCT02878473· Phase 2· University Health Network, Toronto· Source

• Completed

  Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

  NCT03555422· Phase 3· Karyopharm Therapeutics Inc· Source

• Completed

  Ixazomib Rollover Study

  NCT02924272· Phase 2· Takeda· Source

• Completed

  Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

  NCT02788773· Phase 2· Canadian Cancer Trials Group· Source

• Completed

  Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

  NCT02879162· Phase 2· Canadian Cancer Trials Group· Source

• Completed

  Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

  NCT02784171· Phase 2/3· Canadian Cancer Trials Group· Source

• Completed

  PET MRI Study in Patients With Cardiac Sarcoidosis

  NCT03356756· University Health Network, Toronto· Source

• Completed

  Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

  NCT02630693· Phase 2· Canadian Cancer Trials Group· Source

• Completed

  A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

  NCT02614066· Phase 1/2· Kite, A Gilead Company· Source

• Completed

  Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases

  NCT02511522· Canadian Cancer Trials Group· Source

• Completed

  Cone-beam CT Guided Microcoil Localization of Pulmonary Nodules During Video Assisted Thoracic Surgery(VATS)

  NCT02496624· University Health Network, Toronto· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Canadian Cancer Trials Group· Source

• Completed

  Prostate Hypoxia FAZA

  NCT01567800· University Health Network, Toronto· Source

• Completed

  Short Neoadjuvant Hemithoracic IMRT for MPM

  NCT00797719· Phase 1/2· University Health Network, Toronto· Source

• Completed

  Cardiac FDG PET Viability Registry

  NCT00766987· Ottawa Heart Institute Research Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure121 works · 6 trials
• Lung cancer112 works · 20 trials
• Prostate cancer106 works · 12 trials
• Alzheimer disease102 works · 4 trials
• Parkinson disease93 works · 1 trial
• Liver and biliary tract cancer74 works · 9 trials
• Chronic kidney disease73 works · 3 trials
• Spinal cord injury67 works · 4 trials
• Osteoarthritis55 works · 1 trial
• Psoriatic arthritis51 works · 1 trial
• Depression51 works · 5 trials
• Ovarian cancer50 works · 4 trials
• Sarcoma49 works · 5 trials
• Acute myeloid leukaemia48 works · 2 trials
• Melanoma41 works · 6 trials
• Lupus (SLE)40 works · 1 trial
• Ankylosing spondylitis39 works · 0 trials
• Pancreatic cancer37 works · 4 trials
• Bladder cancer29 works · 5 trials
• Psoriasis29 works · 1 trial
• Head and neck cancer27 works · 7 trials
• Type 1 diabetes27 works · 0 trials
• Kidney cancer26 works · 2 trials
• Congenital heart disease26 works · 2 trials
• Dystonia24 works · 0 trials
• Glioblastoma23 works · 0 trials
• Hepatitis C23 works · 1 trial
• Bipolar disorder21 works · 4 trials
• Endometrial cancer18 works · 4 trials
• Myasthenia gravis18 works · 2 trials